Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial

or

Watchlist | Portfolio

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Nuvalent Inc Cl A (NUVL)

Nuvalent Inc Cl A (NUVL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Why Nuvalent Stock Tanked on Tuesday Motley Fool - Tue Oct 17, 2023

The dilution monster stalked the company following the announcement of a new capital-raising effort.

Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire - Mon Oct 16, 2023

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Nuvalent Announces Public Offering of Common Stock PR Newswire - Mon Oct 16, 2023

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC PR Newswire - Fri Oct 13, 2023

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Why Nuvalent Stock Skyrocketed 35% This Week Motley Fool - Thu Oct 5, 2023

Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know.

Why Nuvalent Stock Was Soaring Wednesday Motley Fool - Wed Oct 4, 2023

The company reported preliminary data on a non-small cell lung cancer therapy.

Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile PR Newswire - Wed Oct 4, 2023

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Nuvalent to Participate in Upcoming September Investor Conferences PR Newswire - Thu Aug 31, 2023

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar